Targeted delivery of PARP inhibitors to neuronal mitochondria via biomimetic engineered nanosystems in a mouse model of traumatic brain injury

Sun, Jiejie; Liu, Jingzhou; Gao, Chun‐Hong; Zheng, Jinpeng; Zhang, Jinbang; Ding, Yaning; Gong, Wenbin; Yang, Meiyan; Li, Zhiping; Wang, Yuli; Yang, Yang; Gao, Chunsheng

doi:10.1016/j.actbio.2021.12.023

Cited by 30 publications

(14 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also test the membrane biological property of the nanosystem [ 72 , 73 ]. As it is displayed in Figure S9 (Supporting Information), the MONCs and MONC-PPG nanosystem exhibited comparable hemolysis with the control group, indicating good biocompatibility.…”

Section: Resultsmentioning

confidence: 99%

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Jin

Zhang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Jin

Zhang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…[49] Therefore, a proper drug delivery system is necessary. Sun et al prepared a red blood cell membrane-coated nanostructured lipid carrier (RBCNLC) for the targeted delivery of Olaparib (RBCNLCs-Olaparib) [48] (Figure 2). In the nano-system, RBC is considered as a effective drug carrier with long duration of systemic circulation, showing an accumulation trend from 1 to 4 h and preventing the circulatory clearance of macrophages via the protein CD47 on their surface.…”

Section: Regulation Of Excitotoxicitymentioning

confidence: 99%

Recent Advances in Biomaterials‐Based Therapies for Alleviation and Regeneration of Traumatic Brain Injury

Chen

Zhao

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Traumatic brain injury (TBI), a major public health problem accompanied with numerous complications, usually leads to serve disability and huge financial burden. The adverse and unfavorable pathological environment triggers a series of secondary injuries, resulting in serious loss of nerve function and huge obstacle of endogenous nerve regeneration. With the advances in adaptive tissue regeneration biomaterials, regulation of detrimental microenvironment to reduce the secondary injury and to promote the neurogenesis becomes possible. The adaptive biomaterials could respond and regulate biochemical, cellular, and physiological events in the secondary injury, including excitotoxicity, oxidative stress, and neuroinflammation, to rebuild circumstances suitable for regeneration. In this review, the development of pathology after TBI is discussed, followed by the introduction of adaptive biomaterials based on various pathological characteristics. The adaptive biomaterials carried with neurotrophic factors and stem cells for TBI treatment are then summarized. Finally, the current drawbacks and future perspective of biomaterials for TBI treatment are suggested.

show abstract

“…Nanostructured lipid carriers (RBCNLCs) encapsulated by red blood cells (RBC) were used in brain neuron mitochondria together with C3 and ss31 peptides (C3/SS31-RBCNLCs). The high-concentration delivery of PARP inhibitor olapali (Ola) to brain mitochondria by C3/SS31-RBCNLCs-Ola has effectively improved mitochondrial function ( Sun et al, 2022 ). Various lines of evidence suggested that the inhibition of PARP1 has a protective effect, as some studies found that PARP1 inhibition in ShRNA could promote axon regeneration, while the inhibition of other PARP isoforms would reduce axon regeneration with no improvement of motor function ( Wang et al, 2016 ).…”

Section: The Parthanatos Involved In Traumatic Brain Injurymentioning

confidence: 99%

The role of regulatory necrosis in traumatic brain injury

Nie

Tan

Niu

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a major cause of death and disability in the population worldwide, of which key injury mechanism involving the death of nerve cells. Many recent studies have shown that regulatory necrosis is involved in the pathological process of TBI which includes necroptosis, pyroptosis, ferroptosis, parthanatos, and Cyclophilin D (CypD) mediated necrosis. Therefore, targeting the signaling pathways involved in regulatory necrosis may be an effective strategy to reduce the secondary injury after TBI. Meanwhile, drugs or genes are used as interference factors in various types of regulatory necrosis, so as to explore the potential treatment methods for the secondary injury after TBI. This review summarizes the current progress on regulatory necrosis in TBI.

show abstract

Targeted delivery of PARP inhibitors to neuronal mitochondria via biomimetic engineered nanosystems in a mouse model of traumatic brain injury

Cited by 30 publications

References 48 publications

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Recent Advances in Biomaterials‐Based Therapies for Alleviation and Regeneration of Traumatic Brain Injury

The role of regulatory necrosis in traumatic brain injury

Contact Info

Product

Resources

About